Prescription Patterns of Antiseizure Medication in Adult Patients with Epilepsy in Kazakhstan (2021–2023)
Kalinina D. Aimyshev T. Muxunov A. Utebekov Z. Kyrgyzbay G. Kimadiev D. Zhumabaeva G. Gaipov A. Sarria-Santamera A.
December 2025Multidisciplinary Digital Publishing Institute (MDPI)
Medical sciences
2025#13Issue 4
Background/Objectives: Epilepsy is a major neurological disorder associated with significant comorbidity and treatment challenges. In low- and middle-income countries, access to newer antiseizure medications (ASMs) remains limited, and prescription patterns often rely on older agents. This study aimed to characterize national prescribing patterns of ASMs among patients with epilepsy in Kazakhstan from 2021 to 2023. Methods: We conducted a retrospective observational study using de-identified electronic health record data from the Unified National Electronic Health System of Kazakhstan. All patients with an ICD-10 diagnosis of epilepsy (G40) and at least one ASM prescription during 2021–2023 were included. Prescription frequencies, therapy type, and chronic polytherapy levels were analyzed. Associations between therapy type, age, and comorbidity status were determined. Results: A total of 54,274 patients were identified (median age 42 years; interquartile range (IQR) 31–57). Monotherapy predominated: 61.7% remained on monotherapy, 18.5% remained on polytherapy, and 19.8% had mixed exposure. Carbamazepine and valproic acid were most frequently prescribed (64.3% and 45.6% of patients, respectively). Among those with chronic medication data (n = 15,752), nervous-system drugs were common (70.1%), led by psycholeptics (49.7%); frequently dispensed agents included chlorpromazine (n = 5991), clozapine (n = 1875), and risperidone (n = 1642). Cardiovascular agents were recorded in 37.2% (acetylsalicylic acid n = 4056; atorvastatin n = 2235), and diabetes drugs in 12.1% (metformin n = 1430). Conclusions: Epilepsy treatment in Kazakhstan remains dominated by older broad-spectrum ASMs, while the use of lamotrigine and levetiracetam is steadily increasing. The frequent co-prescription of psychotropic and cardiometabolic drugs underscores the need for coordinated, multidisciplinary care and continued monitoring of prescribing patterns to enhance treatment safety and effectiveness.
anticonvulsants , combination , comorbidity , drug prescriptions , drug therapy , epilepsy
Text of the article Перейти на текст статьи
Department of Medicine, School of Medicine, Nazarbayev University, Astana, Z05P3Y4, Kazakhstan
Epileptology Centre, RSE Medical Centre Hospital of the President’s Affairs Administration of the Republic of Kazakhstan, Astana, Z05M4E8, Kazakhstan
Department of Medicine
Epileptology Centre
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026